GlassScriptPhysician profile
Kara Lea Kern
NPI 1811984321
$6,054.46
in general payments reported to CMS, 2019-2025
31 companies · $455 in 2025
The $455 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,000 · 2020: $1,122 · 2021: $817 · 2022: $956 · 2023: $943 · 2024: $761 · 2025: $455.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,159.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,159.11 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Glaxosmithkline, LLC. | $1,116.90 | 2019-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Astrazeneca Pharmaceuticals LP | $900.89 | 2019-2025 | Farxiga, Airsupra, Breztri |
| Lilly USA, LLC | $833.75 | 2019-2025 | Mounjaro, Jardiance, Zepbound |
| Novo Nordisk INC | $545.75 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Abbvie INC. | $392.08 | 2020-2024 | |
| Sanofi-Aventis U.S. LLC | $301.36 | 2019-2022 | |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $249.84 | 2019-2023 | Xifaxan |
| Abbott Laboratories | $233.35 | 2021-2025 | Freestyle Libre 3, Eterna |
| Amarin Pharma, INC. | $197.42 | 2019-2021 | |
| Amgen INC. | $178.11 | 2019-2023 | Otezla, Repatha |
| Pfizer INC. | $156.93 | 2019-2025 | |
| Dexcom, INC. | $154.25 | 2021-2025 | Dexcom G6 Transmitter |
| Astellas Pharma US INC | $141.81 | 2020-2025 | Veozah |
| E.R. Squibb & Sons, L.L.C. | $91.43 | 2022-2023 | Eliquis, Camzyos |
| Allergan, INC. | $83.81 | 2019-2020 |
Show all 31 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Janssen Pharmaceuticals, INC | $79.56 | 2019-2023 | Spravato |
| Esperion Therapeutics, INC. | $71.94 | 2020-2021 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $65.81 | 2021-2023 | Tradjenta, Jardiance |
| Sumitomo Pharma America, INC. | $38.63 | 2025 | Gemtesa |
| Merck Sharp & Dohme LLC | $29.68 | 2020-2022 | |
| Inspire Medical Systems, INC. | $20.87 | 2023 | Inspire |
| Eisai INC. | $20.33 | 2020 | |
| Azurity Pharmaceuticals, INC. | $20.22 | 2024 | |
| Novartis Pharmaceuticals Corporation | $19.78 | 2019 | |
| Kowa Pharmaceuticals America, INC. | $19.64 | 2025 | Zoryve |
| Genentech USA, INC. | $17.98 | 2020 | |
| Sunovion Pharmaceuticals INC. | $16.78 | 2022 | |
| Idorsia Pharmaceuticals US INC | $14.68 | 2023 | Quviviq |
| Seqirus USA INC | $14.33 | 2019 | |
| Kyowa Kirin, INC. | $14.28 | 2025 | |
| Evofem Biosciences, INC. | $12.27 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Kara Kern listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.